FDA Expands Anktiva Approval for BCG-Unresponsive Bladder CancerOctober 14, 2026 Health 4 Views The FDA has expanded Anktiva approval to treat BCG-unresponsive bladder cancer in adults with high-grade papillary tumors, marking a new evaluation approach.
